Estimating the magnitude of cancer overdiagnosis in Australia

Paul P Glasziou, Mark A Jones, Thanya Pathirana, Alexandra L Barratt, Katy Jl Bell, Paul P Glasziou, Mark A Jones, Thanya Pathirana, Alexandra L Barratt, Katy Jl Bell

Abstract

Objectives: To estimate the proportion of cancer diagnoses in Australia that might reasonably be attributed to overdiagnosis by comparing current and past lifetime risks of cancer.

Design, setting, and participants: Routinely collected Australian Institute of Health and Welfare national data were analysed to estimate recent (2012) and historical (1982) lifetime risks (adjusted for competing risk of death and changes in risk factors) of diagnoses with five cancers: prostate, breast, renal, thyroid cancers, and melanoma.

Main outcome measure: Difference in lifetime risks of cancer diagnosis between 1982 and 2012, interpreted as probable overdiagnosis.

Results: For women, absolute lifetime risk increased by 3.4 percentage points for breast cancer (invasive cancers, 1.7 percentage points), 0.6 percentage point for renal cancer, 1.0 percentage point for thyroid cancer, and 5.1 percentage points for melanoma (invasive melanoma, 0.7 percentage point). An estimated 22% of breast cancers (invasive cancers, 13%), 58% of renal cancers, 73% of thyroid cancers, and 54% of melanomas (invasive melanoma, 15%) were overdiagnosed, or 18% of all cancer diagnoses (8% of invasive cancer diagnoses). For men, absolute lifetime risk increased by 8.2 percentage points for prostate cancer, 0.8 percentage point for renal cancer, 0.4 percentage point for thyroid cancer, and 8.0 percentage points for melanoma (invasive melanoma, 1.5 percentage points). An estimated 42% of prostate cancers, 42% of renal cancers, 73% of thyroid cancers, and 58% of melanomas (invasive melanomas, 22%) were overdiagnosed, or 24% of all cancer diagnoses (16% of invasive cancer diagnoses). Alternative assumptions slightly modified the estimates for overdiagnosis of breast cancer and melanoma.

Conclusions: About 11 000 cancers in women and 18 000 in men may be overdiagnosed each year. Rates of overdiagnosis need to be reduced and health services should monitor emerging areas of overdiagnosis.

Keywords: Cancer; Early detection of cancer; Mass screening; Quality of health care.

© 2019 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
    1. Australian Institute of Health and Welfare . Australia's health 2018 (Cat No. AUS 221; Australia's health series no. 16). Canberra: AIHW, 2018.
    1. Brodersen J, Schwartz LM, Heneghan C, et al. Overdiagnosis: what it is and what it isn't. BMJ Evid Based Med 2018; 23: 1–3.
    1. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102: 605–613.
    1. Esserman LJ, Thompson IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncology 2014; 15: E234–E242.
    1. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate‐specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 2003; 95: 868–878.
    1. Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013; 108: 2205–2240.
    1. Vaccarella S, Franceschi S, Bray F, et al. Worldwide thyroid‐cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 2016; 375: 614–617.
    1. Davies L, Ouellette M, Hunter M, et al. The increasing incidence of small thyroid cancers: where are the cases coming from? Laryngoscope 2010; 120: 2446–2451.
    1. Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ 2015; 350: g7773.
    1. Carter SM, Doust J, Degeling C, et al. A definition and ethical evaluation of overdiagnosis: response to commentaries. J Med Ethics 2016; 42: 722–724.
    1. Fang F, Keating NL, Mucci LA, et al. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst 2010; 102: 307–314.
    1. Smith DP, Calopedos R, Bang A, et al. Increased risk of suicide in New South Wales men with prostate cancer: analysis of linked population‐wide data. PLoS One 2018; 13: e0198679.
    1. Moynihan R, Barratt AL, Buchbinder R, et al. Australia is responding to the complex challenge of overdiagnosis. Med J Aust 2018; 209: 332–334. .
    1. Pathirana TI, Hayden A, Doust J, et al. The lifetime risk of prostate cancer overdiagnosis in Australia. BMJ Open 2019; 9: e022457.
    1. Australian Institute of Health and Welfare . Cancer data in Australia (CAN 122): ACIM books and ACD pivot table. Updated Jan 2019. ; (viewed Feb 2019).
    1. Fay MP, Pfeiffer R, Cronin KA, et al. Age‐conditional probabilities of developing cancer. Stat Med 2003; 22: 1837–1848.
    1. Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010; 102: 170–178.
    1. Jacklyn G, Morrell S, McGeechan K, et al. Carcinoma in situ of the breast in New South Wales, Australia: current status and trends over the last 40 year. Breast 2018; 37: 170–178.
    1. Coory M, Baade P, Aitken J, et al. Trends for in situ and invasive melanoma in Queensland, Australia, 1982–2002. Cancer Causes Control 2006; 17: 21–27.
    1. Aitken JF, Youlden DR, Baade PD, et al. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995–2014. Int J Cancer 2018; 142: 1528–1535.
    1. Giles GG, Armstrong BK, Burton RC, et al. Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994. BMJ 1996; 312: 1121–1125.
    1. Renehan AG, Tyson M, Egger M, et al. Body‐mass index and incidence of cancer: a systematic review and meta‐analysis of prospective observational studies. Lancet 2008; 371: 569–578.
    1. Perez‐Cornago A, Key TJ, Allen NE, et al. Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study. Br J Cancer 2017; 117: 1562–1571.
    1. Johansson M, Carreras‐Torres R, Scelo G, et al. The influence of obesity‐related factors in the etiology of renal cell carcinoma: a mendelian randomization study. PLoS Med 2019; 16: e1002724.
    1. Harikrishna A, Ishak A, Ellinides A, et al. The impact of obesity and insulin resistance on thyroid cancer: a systematic review. Maturitas 2019; 125: 45–49.
    1. Gearon E, Tanamas SK, Stevenson C, et al. Changes in waist circumference independent of weight: implications for population level monitoring of obesity. Prev Med 2018; 111: 378–383.
    1. Oke JL, O'Sullivan JW, Perera R, Nicholson BD. The mapping of cancer incidence and mortality trends in the UK from 1980–2013 reveals a potential for overdiagnosis. Sci Rep 2018; 8: 14663.
    1. Australian Institute of Health and Welfare . Cancer in Australia 2019 (Cat. no. CAN 123; Cancer series no. 119). Canberra: AIHW, 2019.
    1. Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med 2019; 381: 1378–1386.
    1. Office for National Statistics (United Kingdom) . Cancer survival in England: national estimates for patients followed up to 2017. Jan 2019. ; (viewed Oct 2019).
    1. Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020; 77: 38–52.
    1. Ahn HS, Welch HG. South Korea's thyroid‐cancer “epidemic”: turning the tide. N Engl J Med 2015; 373: 2389–2390.
    1. Smith DP, Supramaniam R, Marshall VR, et al. Prostate cancer and prostate‐specific antigen testing in New South Wales. Med J Aust 2008; 189: 315–318. ;
    1. Wernli KJ, Henrikson NB, Morrison CC, et al. Screening for skin cancer in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016; 316: 436–447.
    1. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331: 481.
    1. Bell KJL, Doust J, Glasziou P, et al. Recognizing the potential for overdiagnosis: are high‐sensitivity cardiac troponin assays an example? Ann Intern Med 2019; 170: 259–261.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir